2.50
Hdl Handle:
http://hdl.handle.net/10541/80140
Title:
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Authors:
Ranson, Malcolm R
Abstract:
ZD1839 (Iressa) is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal transduction pathways involved in cell proliferation. Preclinical studies demonstrated that ZD1839 is a promising agent for the treatment of a wide range of tumors and has additive-to-synergistic effects when combined with radiation or chemotherapy in various cell lines and xenografts. Phase I clinical trials have reported that ZD1839 has acceptable tolerability and antitumor activity. In addition to non-small cell lung cancer, phase II/III studies are currently investigating ZD1839 as monotherapy or in combination therapy against prostate, breast, head and neck, gastric, and colorectal tumors.
Affiliation:
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom. malcolm.ranson@man.ac.uk
Citation:
ZD1839 (Iressa): for more than just non-small cell lung cancer. 2002, 7 Suppl 4:16-24 Oncologist
Journal:
The Oncologist
Issue Date:
2002
URI:
http://hdl.handle.net/10541/80140
PubMed ID:
12202784
Type:
Article
Language:
en
ISSN:
1083-7159
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm R-
dc.date.accessioned2009-09-07T15:36:49Z-
dc.date.available2009-09-07T15:36:49Z-
dc.date.issued2002-
dc.identifier.citationZD1839 (Iressa): for more than just non-small cell lung cancer. 2002, 7 Suppl 4:16-24 Oncologisten
dc.identifier.issn1083-7159-
dc.identifier.pmid12202784-
dc.identifier.urihttp://hdl.handle.net/10541/80140-
dc.description.abstractZD1839 (Iressa) is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal transduction pathways involved in cell proliferation. Preclinical studies demonstrated that ZD1839 is a promising agent for the treatment of a wide range of tumors and has additive-to-synergistic effects when combined with radiation or chemotherapy in various cell lines and xenografts. Phase I clinical trials have reported that ZD1839 has acceptable tolerability and antitumor activity. In addition to non-small cell lung cancer, phase II/III studies are currently investigating ZD1839 as monotherapy or in combination therapy against prostate, breast, head and neck, gastric, and colorectal tumors.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectColorectal Canceren
dc.subjectOvarian Canceren
dc.subjectHead and Neck Canceren
dc.subjectProstatic Canceren
dc.subjectCanceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBreast Neoplasms-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshControlled Clinical Trials as Topic-
dc.subject.meshFemale-
dc.subject.meshHead and Neck Neoplasms-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeoplasms-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshProtein-Tyrosine Kinases-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshSignal Transduction-
dc.subject.meshTreatment Outcome-
dc.titleZD1839 (Iressa): for more than just non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom. malcolm.ranson@man.ac.uken
dc.identifier.journalThe Oncologisten
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.